Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review.

Ukon Y, Makino T, Kodama J, Tsukazaki H, Tateiwa D, Yoshikawa H, Kaito T.

Int J Mol Sci. 2019 May 24;20(10). pii: E2557. doi: 10.3390/ijms20102557. Review.

2.

A novel and efficient method for culturing mouse nucleus pulposus cells.

Kushioka J, Kaito T, Chijimatsu R, Okada R, Ishiguro H, Bal Z, Kodama J, Takenaka S, Makino T, Sakai Y, Yoshikawa H.

Spine J. 2019 Apr 12. pii: S1529-9430(19)30124-X. doi: 10.1016/j.spinee.2019.04.005. [Epub ahead of print]

PMID:
30986578
3.

Administration of ONO-2506 suppresses neuropathic pain after spinal cord injury by inhibition of astrocytic activation.

Ishiguro H, Kaito T, Hashimoto K, Kushioka J, Okada R, Tsukazaki H, Kodama J, Bal Z, Ukon Y, Takenaka S, Makino T, Sakai Y, Yoshikawa H.

Spine J. 2019 Apr 8. pii: S1529-9430(19)30125-1. doi: 10.1016/j.spinee.2019.04.006. [Epub ahead of print]

PMID:
30974239
4.

Neoadjuvant Chemotherapy with Taxane and Platinum Followed by Radical Hysterectomy for Stage IB2-IIB Cervical Cancer: Impact of Histology Type on Survival.

Matsuo K, Shimada M, Yamaguchi S, Kigawa J, Tokunaga H, Tabata T, Kodama J, Kawana K, Mikami M, Sugiyama T.

J Clin Med. 2019 Jan 30;8(2). pii: E156. doi: 10.3390/jcm8020156.

5.

Water drainage from Kushiro Coal Mine decreased on the day of all M ≥ 7.5 earthquakes and increased thereafter.

Fujii Y, Ichihara Y, Matsumoto H, Kodama JI, Fukuda D, Dassanayake ABN.

Sci Rep. 2018 Nov 7;8(1):16472. doi: 10.1038/s41598-018-34931-5.

7.

Postoperative decreased levels of D-dimer in patients with gynecologic cancer with enoxaparin and fondaparinux thromboprophylaxis.

Kodama J, Seki N, Fukushima C, Kusumoto T, Nakamura K, Hiramatsu Y.

Mol Clin Oncol. 2013 Jul;1(4):737-744. Epub 2013 May 14.

8.

Three cases of struma ovarii underwent laparoscopic surgery with definite preoperative diagnosis.

Nurliza Binti Md Nor, Kusumoto T, Inoue S, Nakamura K, Seki N, Hongo A, Kodama J, Hiramatsu Y.

Acta Med Okayama. 2013;67(3):191-5.

9.
10.

Stage IB1 cervical cancer patients with an MRI-measured tumor size < or = 2 cm might be candidates for less-radical surgery.

Kodama J, Fukushima C, Kusumoto T, Nakamura K, Seki N, Hongo A, Hiramatsu Y.

Eur J Gynaecol Oncol. 2013;34(1):39-41.

PMID:
23589998
11.

Elevated preoperative plasma D-dimer levels and the incidence of venous thromboembolism in Japanese females with gynecological cancer.

Kodama J, Seki N, Fukushima C, Kusumoto T, Nakamura K, Hongo A, Hiramatsu Y.

Oncol Lett. 2013 Jan;5(1):299-304. Epub 2012 Oct 15.

12.

Changes in soluble fibrin levels during the perioperative period of gynecologic cancer surgery.

Kodama J, Seki N, Fukushima C, Kusumoto T, Nakamura K, Hongo A, Hiramatsu Y.

Oncol Lett. 2012 Nov;4(5):1122-1124. Epub 2012 Aug 31.

13.

[Mechanism of metastasis in cervical cancer].

Kodama J, Hiramatsu Y.

Nihon Rinsho. 2012 Jun;70 Suppl 4:100-3. Japanese. No abstract available.

PMID:
23156225
14.

The mean apparent diffusion coefficient value (ADCmean) on primary cervical cancer is a predictive marker for disease recurrence.

Nakamura K, Joja I, Nagasaka T, Fukushima C, Kusumoto T, Seki N, Hongo A, Kodama J, Hiramatsu Y.

Gynecol Oncol. 2012 Dec;127(3):478-83. doi: 10.1016/j.ygyno.2012.07.123. Epub 2012 Aug 11.

PMID:
22892362
15.

In vitro efficacy of continuous mild heat stress on the antifungal susceptibility of Candida albicans biofilm formation.

Cho T, Nagao J, Imayoshi R, Kodama J, Morotomi T, Kaminishi H.

Biol Pharm Bull. 2012;35(8):1371-3.

16.

Role of emmprin in endometrial cancer.

Nakamura K, Kodama J, Hongo A, Hiramatsu Y.

BMC Cancer. 2012 May 28;12:191. doi: 10.1186/1471-2407-12-191.

18.

Measurement of SUVmax plus ADCmin of the primary tumour is a predictor of prognosis in patients with cervical cancer.

Nakamura K, Joja I, Kodama J, Hongo A, Hiramatsu Y.

Eur J Nucl Med Mol Imaging. 2012 Feb;39(2):283-90. doi: 10.1007/s00259-011-1978-7. Epub 2011 Nov 10.

PMID:
22072286
19.

Measurement of the minimum apparent diffusion coefficient (ADCmin) of the primary tumor and CA125 are predictive of disease recurrence for patients with endometrial cancer.

Nakamura K, Imafuku N, Nishida T, Niwa I, Joja I, Hongo A, Kodama J, Hiramatsu Y.

Gynecol Oncol. 2012 Feb;124(2):335-9. doi: 10.1016/j.ygyno.2011.10.014. Epub 2011 Oct 18.

PMID:
22008707
20.

The measurement of SUVmax of the primary tumor is predictive of prognosis for patients with endometrial cancer.

Nakamura K, Hongo A, Kodama J, Hiramatsu Y.

Gynecol Oncol. 2011 Oct;123(1):82-7. doi: 10.1016/j.ygyno.2011.06.026. Epub 2011 Jul 20.

PMID:
21764107
21.

Factors associated with parametrial involvement in stage IB1 cervical cancer and identification of patients suitable for less radical surgery.

Kodama J, Kusumoto T, Nakamura K, Seki N, Hongo A, Hiramatsu Y.

Gynecol Oncol. 2011 Sep;122(3):491-4. doi: 10.1016/j.ygyno.2011.05.038. Epub 2011 Jun 24.

PMID:
21703671
22.

Fat accumulation in adipose tissues as a risk factor for the development of endometrial cancer.

Nakamura K, Hongo A, Kodama J, Hiramatsu Y.

Oncol Rep. 2011 Jul;26(1):65-71. doi: 10.3892/or.2011.1259. Epub 2011 Apr 13.

PMID:
21491090
23.

Complications and obstetric outcomes after laser conization during pregnancy.

Seki N, Kodama J, Kusumoto T, Nakamura K, Hongo A, Hiramatsu Y.

Eur J Gynaecol Oncol. 2010;31(4):399-401.

PMID:
20882881
24.

The role of hepatocyte growth factor activator inhibitor (HAI)-1 and HAI-2 in endometrial cancer.

Nakamura K, Hongo A, Kodama J, Hiramatsu Y.

Int J Cancer. 2011 Jun 1;128(11):2613-24. doi: 10.1002/ijc.25606. Epub 2010 Oct 4.

25.

Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma.

Nakamura K, Abarzua F, Hongo A, Kodama J, Nasu Y, Kumon H, Hiramatsu Y.

Int J Oncol. 2010 Sep;37(3):605-14.

PMID:
20664929
26.

The predictive value of measurement of SUVmax and SCC-antigen in patients with pretreatment of primary squamous cell carcinoma of cervix.

Nakamura K, Okumura Y, Kodama J, Hongo A, Kanazawa S, Hiramatsu Y.

Gynecol Oncol. 2010 Oct;119(1):81-6. doi: 10.1016/j.ygyno.2010.04.020. Epub 2010 Jun 26.

PMID:
20580064
27.

A pilot study of combination chemotherapy with paclitaxel, pirarubicin, and carboplatin (TPC) for endometrial carcinoma.

Hongo A, Kusumoto T, Nakamura K, Seki N, Kodama J, Hiramatsu Y.

Int J Clin Oncol. 2010 Oct;15(5):476-83. doi: 10.1007/s10147-010-0099-9. Epub 2010 Jun 8.

PMID:
20526888
28.

Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis.

Kodama J, Sasaki A, Masahiro S, Seki N, Kusumoto T, Nakamura K, Hongo A, Hiramatsu Y.

Oncol Lett. 2010 May;1(3):511-513. Epub 2010 May 1.

29.

Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer.

Kusumoto T, Kodama J, Seki N, Nakamura K, Hongo A, Hiramatsu Y.

Oncol Rep. 2010 Apr;23(4):917-25.

PMID:
20204274
30.

α-fetoprotein-producing endometrial adenocarcinoma without an obvious hepatoid component.

Kodama J, Seki N, Yanai H, Kusumoto T, Nakamura K, Hongo A, Hiramatsu Y.

Oncol Lett. 2010 Mar;1(2):243-245. Epub 2010 Mar 1.

31.

The SUVmax of 18F-FDG PET correlates with histological grade in endometrial cancer.

Nakamura K, Kodama J, Okumura Y, Hongo A, Kanazawa S, Hiramatsu Y.

Int J Gynecol Cancer. 2010 Jan;20(1):110-5. doi: 10.1111/IGC.0b013e3181c3a288.

PMID:
20130510
32.

D-dimer level as a risk factor for postoperative venous thromboembolism in Japanese women with gynecologic cancer.

Kodama J, Seki N, Masahiro S, Kusumoto T, Nakamura K, Hongo A, Hiramatsu Y.

Ann Oncol. 2010 Aug;21(8):1651-6. doi: 10.1093/annonc/mdq012. Epub 2010 Feb 3.

PMID:
20129998
33.

Prognostic factors in stage IB-IIB cervical adenocarcinoma patients treated with radical hysterectomy and pelvic lymphadenectomy.

Kodama J, Seki N, Masahiro S, Kusumoto T, Nakamura K, Hongo A, Hiramatsu Y.

J Surg Oncol. 2010 Apr 1;101(5):413-7. doi: 10.1002/jso.21499.

PMID:
20127891
34.

[Magnetic resonance imaging findings on the eyelids of Japanese cadavers for anatomical studies and a comparative examination of their histological pictures].

Ide A, Wakimasu K, Shiba T, Kodama J, Shirasawa N.

Nippon Ganka Gakkai Zasshi. 2009 Dec;113(12):1125-31. Japanese.

PMID:
20058668
35.

The role of hepatocyte growth factor activator inhibitor-1 (HAI-1) as a prognostic indicator in cervical cancer.

Nakamura K, Abarzua F, Hongo A, Kodama J, Nasu Y, Kumon H, Hiramatsu Y.

Int J Oncol. 2009 Aug;35(2):239-48.

PMID:
19578736
36.

Expression of matriptase and clinical outcome of human endometrial cancer.

Nakamura K, Hongo A, Kodama J, Abarzua F, Nasu Y, Kumon H, Hiramatsu Y.

Anticancer Res. 2009 May;29(5):1685-90.

37.

Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer.

Nakamura K, Abarzua F, Kodama J, Hongo A, Nasu Y, Kumon H, Hiramatsu Y.

Int J Oncol. 2009 Feb;34(2):345-53.

PMID:
19148468
38.

Immunohistochemical evaluation of insulin-like growth factor I receptor status in cervical cancer specimens.

Kuramoto H, Hongo A, Liu YX, Ojima Y, Nakamura K, Seki N, Kodama J, Hiramatsu Y.

Acta Med Okayama. 2008 Aug;62(4):251-9.

39.

Hepsin inhibits the cell growth of endometrial cancer.

Nakamura K, Takamoto N, Abarzua F, Hongo A, Kodama J, Nasu Y, Kumon H, Hiramatsu Y.

Int J Mol Med. 2008 Sep;22(3):389-97.

PMID:
18698500
40.

Hepatocyte growth factor activator inhibitor-2 (HAI-2) is a favorable prognosis marker and inhibits cell growth through the apoptotic pathway in cervical cancer.

Nakamura K, Abarzua F, Hongo A, Kodama J, Nasu Y, Kumon H, Hiramatsu Y.

Ann Oncol. 2009 Jan;20(1):63-70. doi: 10.1093/annonc/mdn556. Epub 2008 Aug 9.

PMID:
18689863
41.

Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer.

Nakamura K, Takamoto N, Hongo A, Kodama J, Abrzua F, Nasu Y, Kumon H, Hiramatsu Y.

Oncol Rep. 2008 May;19(5):1085-91.

PMID:
18425362
42.

Expression of the serine protease hepsin and clinical outcome of human endometrial cancer.

Matsuo T, Nakamura K, Takamoto N, Kodama J, Hongo A, Abrzua F, Nasu Y, Kumon H, Hiramatsu Y.

Anticancer Res. 2008 Jan-Feb;28(1A):159-64.

43.

Phase I study of chemoradiation with nedaplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix.

Kodama J, Takemoto M, Seki N, Nakamura K, Hongo A, Moriya S, Kanazawa S, Hiramatsu Y.

Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1300-4. doi: 10.1111/j.1525-1438.2008.01199.x. Epub 2008 Feb 15.

PMID:
18284451
44.

Phase I study of weekly nedaplatin and concurrent pelvic radiotherapy as adjuvant therapy after radical surgery for cervical cancer.

Kodama J, Takemoto M, Seki N, Nakamura K, Hongo A, Kanazawa S, Hiramatsu Y.

Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1037-41. Epub 2007 Nov 16.

PMID:
18021215
45.

Expression of the CXCR4 and CCR7 chemokine receptors in human endometrial cancer.

Kodama J, Hasengaowa, Seki N, Kusumoto T, Hiramatsu Y.

Eur J Gynaecol Oncol. 2007;28(5):370-5.

PMID:
17966215
46.

Versican expression in human cervical cancer.

Kodama J, Hasengaowa, Kusumoto T, Seki N, Matsuo T, Nakamura K, Hongo A, Hiramatsu Y.

Eur J Cancer. 2007 Jun;43(9):1460-6. Epub 2007 Apr 18.

PMID:
17446061
47.

Prognostic factors in pathologic parametrium-positive patients with stage IB-IIB cervical cancer treated by radical surgery and adjuvant therapy.

Kodama J, Seki N, Nakamura K, Hongo A, Hiramatsu Y.

Gynecol Oncol. 2007 Jun;105(3):757-61. Epub 2007 Apr 12.

PMID:
17433424
48.

Chemotherapy for high-risk early-stage endometrial cancer.

Kodama J, Seki N, Hiramatsu Y.

Curr Opin Obstet Gynecol. 2007 Feb;19(1):42-7. Review.

PMID:
17218851
49.

Prognostic significance of stromal versican expression in human endometrial cancer.

Kodama J, Hasengaowa, Kusumoto T, Seki N, Matsuo T, Ojima Y, Nakamura K, Hongo A, Hiramatsu Y.

Ann Oncol. 2007 Feb;18(2):269-74. Epub 2006 Oct 25.

PMID:
17065588
50.

Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer.

Kodama J, Hasengaowa, Kusumoto T, Seki N, Matsuo T, Ojima Y, Nakamura K, Hongo A, Hiramatsu Y.

Ann Oncol. 2007 Jan;18(1):70-6. Epub 2006 Oct 10.

PMID:
17032700

Supplemental Content

Loading ...
Support Center